Provided by Tiger Trade Technology Pte. Ltd.

Perspective Therapeutics

2.88
0.0000
Post-market: 2.910.0300+1.04%19:58 EDT
Volume:11.64M
Turnover:33.39M
Market Cap:328.32M
PE:-2.17
High:2.94
Open:2.89
Low:2.77
Close:2.88
52wk High:6.16
52wk Low:1.96
Shares:114.00M
Float Shares:68.28M
Volume Ratio:7.03
T/O Rate:17.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3300
EPS(LYR):-1.3971
ROE:-39.57%
ROA:-22.28%
PB:1.01
PE(LYR):-2.06

Loading ...

Perspective Therapeutics Q1 net loss widens as grant revenue drops

Reuters
·
May 12

Perspective Therapeutics Q1 EPS $(0.25) Beats $(0.31) Estimate, Sales $76.000K Miss $136.917K Estimate

Benzinga Earnings
·
May 12

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results

THOMSON REUTERS
·
May 12

Perspective Therapeutics Q1 EPS USD -0.25

THOMSON REUTERS
·
May 12

Perspective Therapeutics (CATX) Receives a Buy from JonesTrading

TIPRANKS
·
May 07

Perspective Therapeutics Price Target Maintained With a $11.00/Share by Wedbush

Dow Jones
·
May 05

RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

TIPRANKS
·
May 05

Perspective Therapeutics (CATX) Receives a Buy from Truist Financial

TIPRANKS
·
May 05

Perspective Therapeutics Highlights Alpha-Targeted Oncology Strategy Update

TIPRANKS
·
May 05

Perspective Therapeutics to host analyst event on strategy, enabling technology, pipeline

Reuters
·
Apr 24

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

GlobeNewswire
·
Apr 24

Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), Centessa Pharmaceuticals (CNTA) and Perspective Therapeutics (CATX)

TIPRANKS
·
Apr 20

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), Maravai Lifesciences Holdings (MRVI) and LENZ Therapeutics (LENZ)

TIPRANKS
·
Apr 20

Perspective Therapeutics Price Target Maintained With a $11.00/Share by Wedbush

Dow Jones
·
Apr 20

Perspective Therapeutics (CATX) Receives a Buy from Piper Sandler

TIPRANKS
·
Apr 20

Perspective Therapeutics Highlights Encouraging Interim Neuroendocrine Tumor Data

TIPRANKS
·
Apr 20

BUZZ-Perspective Therapeutics rises as experimental cancer drug shows promise

Reuters
·
Apr 20

Perspective reports results from Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET

TIPRANKS
·
Apr 20

Perspective Therapeutics reports 43% response rate in [212Pb]VMT-α-NET Phase 1/2a trial

Reuters
·
Apr 20

Perspective Therapeutics Presents Updated Interim Data of [212PB]Vmt-Α-Net in Its Ongoing Phase 1/2a Clinical Trial at the 2026 Aacr Annual Meeting

THOMSON REUTERS
·
Apr 20